Biomarkers of renal osteodystrophy type
AssigneesThe Trustees of Columbia University in the City of New York, The Trustees of Indiana University
InventorsThomas L. Nickolas, Sharon Moe, Neal X. Chen
Life of this patent
Estimating the term…
Abstract
Provided herein is a method of treating low turnover renal osteodystrophy in a subject being administered an agent that reduces bone turnover comprising measuring a level of one or more miRNAs in a sample from the subject. The miRNA being measured can include miRNA-30b, miRNA-30c, miRNA-125b and miRNA-155. Administration of the agent that reduces bone turnover can be stopped if the level of the one or more miRNAs measured is lower than a level of the one or more miRNAs measured in a control subject. Administration of the agent that reduces bone turnover can be continued if the level of the one or more miRNAs measured is not lower than a level of the one or more miRNAs measured in a control subject.
Claims11
A method of treating low turnover renal osteodystrophy in a human subject, the method comprising:
- i) administering an anabolic agent to the human subject if a level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof in a blood sample from the human subject is lower than a mean level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof measured in a cohort of subjects having chronic kidney disease and normal or high turnover renal osteodystrophy;
- or
- ii) administering to the human subject an agent that reduces bone turnover if a level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof in a blood sample from the human subject is equal to or higher than a mean level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof measured in a cohort of subjects having chronic kidney disease and normal or high turnover renal osteodystrophy,
- wherein the agent that reduces bone turnover is a vitamin D analog, calcitrol or analogs thereof, a calcimimetic, or an anti-resorptive agent;
- wherein the anti-resorptive agent is alendronate, risedronate, or denosumab.
A method of reducing the risk of fractures associated with low turnover renal osteodystrophy in a human subject in need thereof, the method comprising:
- i) administering an anabolic agent to the human subject if a level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof in a blood sample from the human subject is lower than a mean level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof measured in a cohort of subjects having chronic kidney disease and normal or high turnover renal osteodystrophy;
- or
- ii) administering to the human subject an agent that reduces bone turnover if a level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof in a blood sample from the human subject equal to or higher than a mean level of miRNA-30b, miRNA-30c, miRNA-125b, miRNA-155, or any combination thereof measured in a cohort of subjects having chronic kidney disease and normal or high turnover renal osteodystrophy,
- wherein the agent that reduces bone turnover is a vitamin D analog, calcitrol or analogs thereof, a calcimimetic, or an anti-resorptive agent;
- wherein the anti-resorptive agent is alendronate, risedronate, or denosumab.
Dependencies are inferred from the claim text.